Extruded extended release abuse deterrent pill

1. An oral, extended release, abuse deterrent pill comprising:

(i) 4 wt % to 35 wt % of an active substance susceptible to abuse, wherein the active substance is oxycodone, hydrocodone, hydromorphone, morphine, methadone, or pharmaceutical acceptable salts thereof;

(ii) 38 wt % to 42 wt % of polyethylene oxide as a matrix agent, wherein the matrix agent has an average molecular weight between 50K Daltons and 150K Daltons;

(iii) 15 wt % to 45 wt % of hydroxypropyl methylcellulose as a controlled release agent;

(iv) 0.2 wt % to 20 wt % polyethylene glycol as a plasticizer;

wherein the active substance susceptible to abuse has an extended release profile,

wherein the pill exhibits less than a 10% increase in the release of the active substance in a simulated alcoholic gastric fluid environment,

wherein the pill has at least 50 wt % of particles with a particle size greater than 0.5 mm following physical or mechanical manipulation of the pill, and

wherein the pill is a formed, uniform extrudate having a uniform blend of active, matrix agent, controlled release agent and plasticizer, and is directly formed from an extrusion process.

2. The oral, extended release, abuse deterrent pill of claim 1 , wherein the active substance is present at 5 to 200 mg.

3. The oral, extended release, abuse deterrent pill of claim 1 , wherein the plasticizer is polyethylene glycol having an average molecular weight of less than 10K Daltons.

4. The oral, extended release, abuse deterrent pill of claim 1 , wherein the pill further comprises at least one preservative or antioxidant selected from the group consisting of silica, sodium laurel sulfate, citric acid, butylated hydroxytoluene (BHT), ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), erythorbic acid, hypophosphorous acid, lactobionic acid, monothioglycerol, potassium metabisulfite, propyl gallate, racemethionine, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, stannous chloride, sulfur dioxide and tocopherols.

5. The oral, extended release, abuse deterrent pill of claim 1 ,

wherein between 20% and 40% of the active substance is released from the pill after 1 hour of exposure to simulated gastric fluid,

wherein between 35% and 55% of the active substance is released from the pill after 2 hours of exposure to simulated gastric fluid,

wherein between 55% and 75% of the active substance is released from the pill after 4 hours of exposure to simulated gastric fluid,

wherein between 70% and 90% of the active substance is released from the pill after 6 hours of exposure to simulated gastric fluid, and

wherein not less than 80% of the active substance is released from the pill after 8 hours of exposure to simulated gastric fluid.

6. The oral, extended release, abuse deterrent pill of claim 1 , wherein the physical barrier is the pill has at least a 2× increase in small volume extraction viscosity compared to similar pills.

7. The oral, extended release, abuse deterrent pill of claim 1 , wherein the purity of the drug following alcohol extraction is <40%.

8. The oral, extended release, abuse deterrent dosage formulation of claim 1 formed using a tablet press and cured using preceding, simultaneous, or subsequent heat.

9. The oral, extended release, abuse deterrent pill of claim 1 formed using a hot melt extrusion process and a forming unit.

10. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 4 wt % to 6 wt % of the active substance susceptible to abuse;

(iii) 36 wt % to 39 wt % of hydroxypropyl methylcellulose; and

(iv) 14 wt % to 17 wt % of polyethylene glycol.

11. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 32 wt % to 35 wt % of the active substance susceptible to abuse;

(iii) 18 wt % to 22 wt % of hydroxypropyl methylcellulose; and

(iv) 4 wt % to 6 wt % of polyethylene glycol.

12. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 6 wt % to 9 wt % of the active substance susceptible to abuse;

(iii) 31 wt % to 38 wt % of hydroxypropyl methylcellulose; and

(iv) 16 wt % to 19 wt % of polyethylene glycol.

13. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 8 wt % to 12 wt % of the active substance susceptible to abuse;

(iii) 29 wt % to 35 wt % of hydroxypropyl methylcellulose; and

(iv) 16 wt % to 19 wt % of polyethylene glycol.

14. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 13 wt % to 17 wt % of the active substance susceptible to abuse;

(iii) 27 wt % to 31 wt % of hydroxypropyl methylcellulose; and

(iv) 13 wt % to 16 wt % of polyethylene glycol.

15. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 18 wt % to 22 wt % of the active substance susceptible to abuse;

(iii) 27 wt % to 31 wt % of hydroxypropyl methylcellulose; and

(iv) 8 wt % to 11 wt % of polyethylene glycol.

16. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 28 wt % to 32 wt % of the active substance susceptible to abuse;

(iii) 26 wt % to 30 wt % of hydroxypropyl methylcellulose; and

(iv) 0.2 wt % to 5 wt % of polyethylene glycol.

17. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 28 wt % to 32 wt % of the active substance susceptible to abuse;

(iii) 26 wt % to 30 wt % of hydroxypropyl methylcellulose; and

(iv) 0.2 wt % to 0.3 wt % of polyethylene glycol.

18. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 6 wt % to 9 wt % of the active substance susceptible to abuse;

(iii) 31 wt % to 38 wt % of hydroxypropyl methylcellulose; and

(iv) 10 wt % to 20 wt % of polyethylene glycol.

19. The oral, extended release, abuse deterrent pill of claim 1 , comprising:

(i) 8 wt % to 12 wt % of the active substance susceptible to abuse;

(iii) 29 wt % to 35 wt % of hydroxypropyl methylcellulose; and

(iv) 10 wt % to 20 wt % of polyethylene glycol.